REPORTS

Let’s Pullulate and Expand Your Business

Neisseria meningitidis Infections Drug Market - Global Professional Analysis and Forecast to 2026

Mar 19, 2020  |  217 PAGES  |  REPORT CODE: CMM272652
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Neisseria meningitidis Infections Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.0% during the forecast period.

This report presents the market size and development trends by detailing the Neisseria meningitidis Infections Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Neisseria meningitidis Infections Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Neisseria meningitidis Infections Drug industry and will help you to build a panoramic view of the industrial development.

Neisseria meningitidis Infections Drug Market, By Type:

  • MGBBP-3

  • NCL-195

  • TP-10

  • Others

Neisseria meningitidis Infections Drug Market, By Application:

  • Hospital

  • Clinic

  • Others

Some of the leading players are as follows:

  • Beijing Minhai Biotechnology Co Ltd

  • Wellstat Vaccines LLC

  • GlaxoSmithKline Plc

  • Sanofi Pasteur SA

  • JN-International Medical Corp

  • Biological E Ltd

  • Pfizer Inc

  • Panacea Biotec Ltd

  • China National Pharmaceutical Group Corp

  • Griffith University

  • Serum Institute of India Ltd

  • ImmunoBiology Ltd

  • MGB Biopharma Ltd

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Neisseria meningitidis Infections Drug Market: Technology Type Analysis

  • 4.1 Neisseria meningitidis Infections Drug Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Neisseria meningitidis Infections Drug Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 MGBBP-3

    • 4.3.2 NCL-195

    • 4.3.3 TP-10

    • 4.3.4 Others

5 Neisseria meningitidis Infections Drug Market: Product Analysis

  • 5.1 Neisseria meningitidis Infections Drug Product Market Share Analysis, 2018 & 2026

  • 5.2 Neisseria meningitidis Infections Drug Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Neisseria meningitidis Infections Drug Market: Application Analysis

  • 6.1 Neisseria meningitidis Infections Drug Application Market Share Analysis, 2018 & 2026

  • 6.2 Neisseria meningitidis Infections Drug Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Hospital

    • 6.3.2 Clinic

    • 6.3.3 Others

7 Neisseria meningitidis Infections Drug Market: Regional Analysis

  • 7.1 Neisseria meningitidis Infections Drug Regional Market Share Analysis, 2018 & 2026

  • 7.2 Neisseria meningitidis Infections Drug Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Beijing Minhai Biotechnology Co Ltd

    • 9.1.1 Beijing Minhai Biotechnology Co Ltd Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Wellstat Vaccines LLC

    • 9.2.1 Wellstat Vaccines LLC Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 GlaxoSmithKline Plc

    • 9.3.1 GlaxoSmithKline Plc Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Sanofi Pasteur SA

    • 9.4.1 Sanofi Pasteur SA Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 JN-International Medical Corp

    • 9.5.1 JN-International Medical Corp Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Biological E Ltd

    • 9.6.1 Biological E Ltd Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Pfizer Inc

    • 9.7.1 Pfizer Inc Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Panacea Biotec Ltd

    • 9.8.1 Panacea Biotec Ltd Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 China National Pharmaceutical Group Corp

    • 9.9.1 China National Pharmaceutical Group Corp Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Griffith University

    • 9.10.1 Griffith University Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Serum Institute of India Ltd

    • 9.11.1 Serum Institute of India Ltd Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 ImmunoBiology Ltd

    • 9.12.1 ImmunoBiology Ltd Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 MGB Biopharma Ltd

    • 9.13.1 MGB Biopharma Ltd Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

 

The List of Tables and Figures (Totals 80 Figures and 130 Tables)

  • Figure MGBBP-3 Neisseria meningitidis Infections Drug market, 2015 - 2026 (USD Million)

  • Figure NCL-195 Neisseria meningitidis Infections Drug market, 2015 - 2026 (USD Million)

  • Figure TP-10 Neisseria meningitidis Infections Drug market, 2015 - 2026 (USD Million)

  • Figure Others Neisseria meningitidis Infections Drug market, 2015 - 2026 (USD Million)

  • Figure Hospital market, 2015 - 2026 (USD Million)

  • Figure Clinic market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Neisseria meningitidis Infections Drug market, by country, 2015 - 2026 (USD Million)

  • Table North America Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table North America Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table North America Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Canada Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Canada Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Europe Neisseria meningitidis Infections Drug market, by country, 2015 - 2026 (USD Million)

  • Table Europe Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Europe Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Europe Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Germany Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Germany Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table France Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table France Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Italy Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Italy Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Spain Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Spain Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neisseria meningitidis Infections Drug market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table China Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table China Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Japan Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Japan Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table India Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table India Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Neisseria meningitidis Infections Drug market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table MEA Neisseria meningitidis Infections Drug market, by country, 2015 - 2026 (USD Million)

  • Table MEA Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table MEA Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table MEA Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Neisseria meningitidis Infections Drug market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Neisseria meningitidis Infections Drug market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Neisseria meningitidis Infections Drug market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Beijing Minhai Biotechnology Co Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Wellstat Vaccines LLC Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GlaxoSmithKline Plc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi Pasteur SA Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table JN-International Medical Corp Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biological E Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Inc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Panacea Biotec Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table China National Pharmaceutical Group Corp Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Griffith University Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Serum Institute of India Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table ImmunoBiology Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table MGB Biopharma Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top